In addition, we found that the expression level of SUMO4 was positively correlated with sensitivity to a variety of targeted or chemotherapeutic drugs, including gemcitabine, paclitaxel, and doxorubicin, so PAAD patients with high expression of SUMO4 may have a better response to gemcitabine and paclitaxel. Here, SUMO4 is linked to pancreatic adenocarcinoma.